Vanguard Group
PRPH

Vanguard Group’s ProPhase Labs PRPH Stock Holding History

Vanguard Group’s Portfolio PRPH Stock Details PRPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$23.8K Hold
53,192
– – ﹤0.01% 4298
2025
Q3 		$244K Buy
53,192
+12,365
+30% +$47.8K ﹤0.01% 4095
2025
Q2 		$160K Hold
40,827
– – ﹤0.01% 4107
2025
Q1 		$165K Sell
40,827
-24,676
-38% -$113K ﹤0.01% 4090
2024
Q4 		$496K Sell
65,503
-92
-0.1% -$1.29K ﹤0.01% 3953
2024
Q3 		$1.59M Hold
65,595
– – ﹤0.01% 3627
2024
Q2 		$2.74M Buy
65,595
+3,719
+6% +$195K ﹤0.01% 3465
2024
Q1 		$4M Buy
61,876
+941
+2% +$47.7K ﹤0.01% 3383
2023
Q4 		$2.75M Buy
60,935
+751
+1% +$34.2K ﹤0.01% 3485
2023
Q3 		$2.63M Hold
60,184
– – ﹤0.01% 3494
2023
Q2 		$4.37M Sell
60,184
-1,482
-2% -$121K ﹤0.01% 3371
2023
Q1 		$4.7M Buy
61,666
+2,829
+5% +$228K ﹤0.01% 3334
2022
Q4 		$5.67M Buy
58,837
+616
+1% +$66.6K ﹤0.01% 3246
2022
Q3 		$6.57M Sell
58,221
-1,800
-3% -$209K ﹤0.01% 3170
2022
Q2 		$7.61M Buy
60,021
+8,760
+17% +$770K ﹤0.01% 3137
2022
Q1 		$3.59M Buy
51,261
+1,467
+3% +$102K ﹤0.01% 3681
2021
Q4 		$3.57M Buy
49,794
+3,060
+7% +$190K ﹤0.01% 3793
2021
Q3 		$2.43M Buy
46,734
+100
+0.2% +$5.96K ﹤0.01% 3997
2021
Q2 		$2.89M Buy
46,634
+33,723
+261% +$1.89M ﹤0.01% 3850
2021
Q1 		$955K Buy
12,911
+6,582
+104% +$632K ﹤0.01% 4022
2020
Q4 		$581K Buy
6,329
+2,116
+50% +$177K ﹤0.01% 3934
2020
Q3 		$146K Buy
4,213
+10
+0.2% +$240 ﹤0.01% 3982
2020
Q2 		$61K Hold
4,203
– – ﹤0.01% 4020
2020
Q1 		$80K Hold
4,203
– – ﹤0.01% 3967
2019
Q4 		$83K Hold
4,203
– – ﹤0.01% 4023
2019
Q3 		$77K Hold
4,203
– – ﹤0.01% 4054
2019
Q2 		$90K Hold
4,203
– – ﹤0.01% 4061
2019
Q1 		$127K Buy
4,203
+232
+6% +$7.14K ﹤0.01% 3988
2018
Q4 		$125K Buy
3,971
+745
+23% +$22.7K ﹤0.01% 3968
2018
Q3 		$97K Buy
3,226
+1,003
+45% +$30.3K ﹤0.01% 4077
2018
Q2 		$72K Buy
2,223
+290
+15% +$9.6K ﹤0.01% 4081
2018
Q1 		$57K Buy
+1,933
New +$49.1K ﹤0.01% 4064
2017
Q4 		– Sell
-3,313
Closed -$70K – 4074
2017
Q3 		$70K Buy
3,313
+1,250
+61% +$26.9K ﹤0.01% 4009
2017
Q2 		$43K Sell
2,063
-5,344
-72% -$107K ﹤0.01% 4035
2017
Q1 		$169K Hold
7,407
– – ﹤0.01% 3929
2016
Q4 		$148K Hold
7,407
– – ﹤0.01% 3933
2016
Q3 		$143K Buy
7,407
+47
+0.6% +$807 ﹤0.01% 3947
2016
Q2 		$96K Sell
7,360
-5,764
-44% -$77.7K ﹤0.01% 4028
2016
Q1 		$160K Buy
13,124
+75
+0.6% +$939 ﹤0.01% 3981
2015
Q4 		$196K Hold
13,049
– – ﹤0.01% 4018
2015
Q3 		$206K Hold
13,049
– – ﹤0.01% 4026
2015
Q2 		$176K Buy
13,049
+70
+0.5% +$938 ﹤0.01% 4063
2015
Q1 		$170K Hold
12,979
– – ﹤0.01% 4017
2014
Q4 		$186K Hold
12,979
– – ﹤0.01% 3925
2014
Q3 		$182K Buy
12,979
+50
+0.4% +$778 ﹤0.01% 3904
2014
Q2 		$219K Buy
12,929
+530
+4% +$9.81K ﹤0.01% 3842
2014
Q1 		$248K Buy
12,399
+3,944
+47% +$74.8K ﹤0.01% 3788
2013
Q4 		$140K Hold
8,455
– – ﹤0.01% 3798
2013
Q3 		$152K Hold
8,455
– – ﹤0.01% 3736
2013
Q2 		$131K Buy
+8,455
New +$132K ﹤0.01% 3699

Other funds holding PRPH

SC
Sykon Capital Harrison, New York $325M AUM 19.22% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group's PRPH Position: Q4 2025 in Review

Vanguard Group held its ProPhase Labs (PRPH) position steady in Q4 2025 at 53,192 shares worth $23.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4298.

Vanguard Group first reported a position in PRPH in Q2 2013 and has held it in 50 quarters since. The position peaked at $7.61M in Q2 2022. 17 funds tracked by Wall St. Rank hold PRPH as of Q4 2025.

  • Vanguard Group held 53,192 shares of ProPhase Labs worth $23.8K as of Q4 2025.
  • Vanguard Group left its ProPhase Labs share count unchanged in Q4 2025.
  • ProPhase Labs made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4298 holding.
  • Vanguard Group first reported a position in ProPhase Labs in Q2 2013 and has held it in 50 quarters since.
  • Vanguard Group's ProPhase Labs position peaked at $7.61M in Q2 2022.
  • 17 funds tracked by Wall St. Rank held ProPhase Labs as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.